FreeStyle Libre 3 and 3 Plus are continuous glucose monitoring devices indicated for the management of diabetes in patients aged 4 years and older.

Sonelokimab receives FDA Fast Track status for palmoplantar pustulosis following phase 2 trial data showing significant symptom reduction.

Additional benefits seen for diastolic blood pressure and concentrations of triglycerides and aspartate aminotransferase.

Of 38 paused databases on October 28, 2025, 33 were vaccination-related topics; only one was updated as of December 2, 2025 ...

Seventy-one percent of patients had pathological complete response; 7% experienced grade 3 treatment-related adverse events.

AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.

Intravenous tenecteplase does not improve vision recovery and is associated with greater incidence of adverse events ...

Significantly longer progression-free survival seen with addition of palbociclib to maintenance anti-HER2 and endocrine therapies.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in patients with type 2 diabetes (T2D) inadequately ...

Findings from the LEAP2MONO study support the regulatory submission of venglustat for treatment of type 3 Gaucher disease.

The FDA has requested new human factors and pharmacology studies for Anaphylm sublingual film following deficiencies in original NDA packaging data.

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...